Overview
Compare with MediWound Ltd., Charlie's Holdings, Inc. or FITLIFE BRANDS, INC., or pick any stock.
- TickerBON on Nasdaq1
- IndustryMedicinal Chemicals & Botanical Products1
- HeadquartersShaanxi, China1
- Incorporated inCayman Islands3
- Business addressRoom 601, Block C, Gazelle Valley, No.69, Jinye Road, High-Tech Zone, Xian, Shaanxi, F4 7100763
- Filer categoryNon-accelerated filer, Emerging growth company3
See how the biggest companies compare on our leaderboards
License (Registration No.: 6101012116403) from the Xi’an Administration for Industry and Commerce.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
20.8%Gross margin2
-8.7%Operating margin2
-10.7%Net margin2
-21.7%Revenue growth, 20252
-3.5%Return on equity2
0.01×Debt to equity2
$134.3KFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Fragrance Compounds brought in 43% of the revenue Bon Natural Life Ltd broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Fragrance Compounds | $14.3M | $4.9M | $8.1M |
| Bioactive Food Ingredients | $6.5M | $12.2M | $7.3M |
| Health Supplements (Solid Drinks) | $8.7M | $6.7M | $3.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue79¢$14.8M
- Research and development4¢$754.2K
- Other costs13¢$2.4M
- Interest2¢$366.2K
- Income tax2¢$339.4K
Out of $18.7M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending5¢$6.8K
- Kept or used elsewhere95¢$134.3K
Out of $141.1K of cash from operations.2
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| REVENUE | $18.7M | $23.8M | $29.5M |
| COST OF REVENUE | -$14.8M | -$16.7M | -$20.7M |
| GROSS PROFIT | $3.9M | $7.1M | $8.8M |
| Selling expenses | -$436.9K | -$270.6K | -$293.7K |
| General and administrative expenses | -$4.3M | -$3.3M | -$2.3M |
| Research and development expenses | -$754.2K | -$1.6M | -$298.5K |
| TOTAL OPERATING EXPENSES | -$5.5M | -$5.2M | -$2.9M |
| (LOSS) INCOME FROM OPERATIONS | -$1.6M | $1.9M | $5.9M |
| Interest income | $867 | $393 | $9.4K |
| Interest expense | -$366.2K | -$303.3K | -$238.2K |
| Government subsidiaries | $37.3K | $63.5K | $25.4K |
| Gain (loss) on disposal of subsidiaries | $160.9K | ||
| Other income (expenses) | $80.3K | -$918.2K | -$160.3K |
| TOTL OTHER EXPENSES, NET | -$86.8K | -$1.2M | -$363.6K |
| INCOME BEFORE INCOME TAX PROVISION | -$1.7M | $715.9K | $5.6M |
| INCOME TAX PROVISION | $339.4K | $351.2K | $1.0M |
| NET (LOSS) INCOME FROM CONTINUING OPERATIONS | -$2.0M | $364.8K | $4.6M |
| Net loss from the sale of the Gansu subsidiary | -$19.5K | -$17.9K | |
| NET (LOSS) INCOME | -$2.0M | $345.2K | $4.6M |
| Less: net loss attributable to non-controlling interest | -$54.7K | -$52.9K | -$43.3K |
| NET (LOSS) INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | -$2.0M | $398.2K | $4.6M |
| Total foreign currency translation adjustment | -$298.9K | $1.1M | -$1.0M |
| TOTAL COMPREHENSIVE (LOSS) INCOME | -$2.3M | $1.4M | $3.5M |
| Less: comprehensive loss attributable to non-controlling interest | -$55.4K | -$54.3K | -$33.3K |
| COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | -$2.3M | $1.5M | $3.5M |
| Basic | -$0.72 | $4.17 | $125.72 |
| Diluted | -$0.72 | $4.14 | $124.92 |
| Basic | 2.8M shares | 95.5K shares | 36.6K shares |
| Diluted | 2.8M shares | 96.1K shares | 36.8K shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 7 quarters (quarterly), latest first.2
| Period ending | 2025-09-30 | 2024-09-30 | 2024-02-29 | 2023-09-30 | 2023-01-31 |
|---|---|---|---|---|---|
| Cash | $500.0K | $80.5K | |||
| Restricted cash | $2.5M | $576.7K | |||
| Accounts receivable, net | $11.0M | $11.8M | |||
| Inventories, net | $3.3M | $1.6M | |||
| Advances to suppliers, net | $15.9M | $14.5M | |||
| Due from related parties | $527.4K | $33.2K | |||
| Prepaid expenses and other current assets | $8.7M | $4.3M | |||
| Current assets held for sale associated with the sale of the Gansu subsidiary | $7.0M | ||||
| TOTAL CURRENT ASSETS | $45.8M | $39.8M | |||
| Property, plant and equipment, net | $18.2M | $15.0M | |||
| Intangible assets, net | $6.4M | $777.0K | |||
| Right-of-use lease assets, net | $113.2K | $141.9K | |||
| Non-current other receivables | $14.7M | ||||
| Deferred tax assets, net | $1.4K | ||||
| Non-current assets held for sale associated with the sale of the Gansu subsidiary | $6.0M | ||||
| TOTAL NON-CURRENT ASSETS | $39.4M | $22.0M | |||
| TOTAL ASSETS | $85.2M | $61.8M | |||
| Short-term loans | $10.2M | $5.7M | |||
| Current portion of long-term loans | $1.1M | $461.8K | |||
| Accounts payable | $7.6M | $3.4M | |||
| Due to related parties | $134.1K | $244.9K | |||
| Taxes payable | $4.9M | $3.7M | |||
| Deferred revenue | $219.7K | $506.8K | |||
| Accrued expenses and other current liabilities | $2.0M | $2.2M | |||
| Operating lease liabilities, current | $76.8K | $148.9K | |||
| Current liabilities held for sale associated with the sale of the Gansu subsidiary | $11.5K | ||||
| TOTAL CURRENT LIABILITIES | $26.3M | $16.4M | |||
| Long-term loans | $842.8K | $970.1K | |||
| Operating lease liability, non-current | $36.6K | ||||
| TOTAL NON-CURRENT LIABILITIES | $879.4K | $970.1K | |||
| TOTAL LIABILITIES | $27.2M | $17.4M | |||
| Additional paid-in capital | $40.8M | $25.0M | |||
| Statutory reserve | $2.8M | $2.7M | |||
| Retained earnings | $16.6M | $18.7M | |||
| Accumulated other comprehensive (loss) | -$2.9M | -$2.6M | |||
| TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS EQUITY | $57.6M | $43.9M | |||
| NON-CONTROLLING INTEREST | $447.1K | $442.8K | |||
| TOTAL SHAREHOLDERS EQUITY | $58.0M | $44.3M | $36.0M | ||
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $85.2M | $61.8M | |||
| Common stock, par value | $0.00 | ||||
| Common stock, shares authorized | 270.0M shares | ||||
| Common stock, shares outstanding | 11.0K shares |
| Period ending | 2025-09-30 | 2024-09-30 | 2024-02-29 | 2023-09-30 | 2023-01-31 | 2022-09-30 | 2019-11-30 |
|---|---|---|---|---|---|---|---|
| Cash | $500.0K | $80.5K | |||||
| Restricted cash | $2.5M | $576.7K | |||||
| Accounts receivable, net | $11.0M | $11.8M | |||||
| Inventories, net | $3.3M | $1.6M | |||||
| Advances to suppliers, net | $15.9M | $14.5M | |||||
| Due from related parties | $527.4K | $33.2K | |||||
| Prepaid expenses and other current assets | $8.7M | $4.3M | |||||
| Current assets held for sale associated with the sale of the Gansu subsidiary | $7.0M | ||||||
| TOTAL CURRENT ASSETS | $45.8M | $39.8M | |||||
| Property, plant and equipment, net | $18.2M | $15.0M | |||||
| Intangible assets, net | $6.4M | $777.0K | |||||
| Right-of-use lease assets, net | $113.2K | $141.9K | |||||
| Non-current other receivables | $14.7M | ||||||
| Deferred tax assets, net | $1.4K | ||||||
| Non-current assets held for sale associated with the sale of the Gansu subsidiary | $6.0M | ||||||
| TOTAL NON-CURRENT ASSETS | $39.4M | $22.0M | |||||
| TOTAL ASSETS | $85.2M | $61.8M | |||||
| Short-term loans | $10.2M | $5.7M | |||||
| Current portion of long-term loans | $1.1M | $461.8K | |||||
| Accounts payable | $7.6M | $3.4M | |||||
| Due to related parties | $134.1K | $244.9K | |||||
| Taxes payable | $4.9M | $3.7M | |||||
| Deferred revenue | $219.7K | $506.8K | |||||
| Accrued expenses and other current liabilities | $2.0M | $2.2M | |||||
| Operating lease liabilities, current | $76.8K | $148.9K | |||||
| Current liabilities held for sale associated with the sale of the Gansu subsidiary | $11.5K | ||||||
| TOTAL CURRENT LIABILITIES | $26.3M | $16.4M | |||||
| Long-term loans | $842.8K | $970.1K | |||||
| Operating lease liability, non-current | $36.6K | ||||||
| TOTAL NON-CURRENT LIABILITIES | $879.4K | $970.1K | |||||
| TOTAL LIABILITIES | $27.2M | $17.4M | |||||
| Additional paid-in capital | $40.8M | $25.0M | |||||
| Statutory reserve | $2.8M | $2.7M | |||||
| Retained earnings | $16.6M | $18.7M | |||||
| Accumulated other comprehensive (loss) | -$2.9M | -$2.6M | |||||
| TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS EQUITY | $57.6M | $43.9M | |||||
| NON-CONTROLLING INTEREST | $447.1K | $442.8K | |||||
| TOTAL SHAREHOLDERS EQUITY | $58.0M | $44.3M | $36.0M | $30.1M | |||
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $85.2M | $61.8M | |||||
| Common stock, par value | $0.00 | $0.00 | |||||
| Common stock, shares authorized | 270.0M shares | 45.0M shares | |||||
| Common stock, shares outstanding | 11.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Net (loss) income | -$2.0M | $345.2K | $4.6M |
| Less: net loss from discontinued operations | -$19.5K | -$17.9K | |
| NET (LOSS) INCOME FROM CONTINUING OPERATIONS | -$2.0M | $364.8K | $4.6M |
| Allowance for doubutful accounts | $693.8K | $1.0M | |
| Depreciation and amortization | $1.1M | $1.1M | $949.5K |
| Inventory reserve (recovery) | $432.8K | -$990 | -$5.8K |
| Deferred income tax | $1.4K | ||
| Amortization of operating lease right-of-use assets | $198.4K | $170.2K | $228.6K |
| Share-based compensation | $1.4M | $1.3M | $349.4K |
| (Gain) loss on disposal of subsidiaries | -$160.9K | ||
| Accounts receivable | -$108.8K | -$6.8M | $2.1M |
| Inventories | -$2.2M | -$530.6K | $721.4K |
| Advance to supplies, net | -$1.7M | -$5.6M | -$4.6M |
| Prepaid expenses and other current assets | -$11.7M | -$7.4M | -$2.2M |
| Accounts payable | $6.1M | $1.9M | $833.5K |
| Operating lease liabilities | -$33.0K | -$232.1K | |
| Taxes payable | $1.3M | $832.5K | $1.6M |
| Deferred revenue | -$276.2K | $385.8K | -$80.2K |
| Accrued expenses and other current liabilities | $7.2M | $5.5M | $2.1M |
| Net cash provided by (used in) operating activities from continuing operations | $141.1K | -$7.7M | $6.3M |
| Net cash used in operating activities from discontinued operations | -$14.6K | -$7.0M | |
| Net cash provided by (used in) operating activities | $141.1K | -$7.7M | -$616.9K |
| Purchase of short-term investments | -$67 | ||
| Proceeds upon redemption of short-term investments | $65 | ||
| Purchase of property and equipment | -$6.8K | -$7.0K | -$61.9K |
| Capital expenditure on construction-in-progress | -$4.4M | ||
| Purchase of intangible assets | -$5.6M | -$669.2K | |
| Proceeds of borrowings to related parties | $5.6K | ||
| Net cash used in investing activities from continuing operations | -$10.0M | -$7.0K | -$725.5K |
| Net cash used in investing activities from discontinued operations | -$8.7K | -$460.1K | |
| Net cash used in investing activities | -$10.0M | -$15.7K | -$1.2M |
| Net proceeds from issuance of ordinary shares | $10.7M | $5.6M | $2.0M |
| Proceeds from short-term loans | $12.0M | $4.3M | $2.9M |
| Proceeds from long-term loans | $970.5K | $694.0K | $1.1M |
| Repayment of short-term loans | -$7.3M | -$1.5M | -$2.7M |
| Repayment of long-term loans | -$340.1K | -$451.3K | -$2.1M |
| Proceeds from (repayment of) borrowings from related parties | -$578.9K | $205.2K | $10.4K |
| Proceeds from (repayment of) third party loans | -$96.1K | ||
| Proceeds from (repayment of) finance lease | -$26.5K | ||
| Net cash provided by financing activities from continuing operations | $15.5M | $8.8M | $1.2M |
| Net cash provided by financing activities from discontinued operations | $5.0K | $3.1K | |
| Net cash provided by financing activities | $15.5M | $8.8M | $1.2M |
| Effect of changes of foreign exchange rates on cash | $7.4K | -$469.8K | -$80.8K |
| Net increase (decrease) in cash and restricted cash | $5.6M | $545.9K | -$728.1K |
| Cash paid for interest expenses | $324.0K | $303.3K | $238.2K |
| Cash paid for income taxes | $478.7K | ||
| Exercise of options | $2 | ||
| Unpaid purchase of property and equipment | $403.3K |
No quarter-by-quarter statement was filed.
Corporate structure
Bon Natural Life Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Bon Natural Life Ltd
- East West Capital, LLC Filed SCHEDULE 13G/A on Bon Natural Life Ltd, latest Mar 27, 2025 (3 filings since Mar 17, 2025)
- Bon Natural Life Ltd Shaanxi, China
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Bon Natural Life Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $22.9M2 Sep 30, 2025 | $18.7M2 Sep 30, 2024 | +22.2% |
| Accumulated depreciation | $4.7M2 Sep 30, 2025 | $3.7M2 Sep 30, 2024 | +26.9% |
| Property and equipment, net | $18.2M2 Sep 30, 2025 | $15.0M2 Sep 30, 2024 | +21.0% |
| Operating-lease assets (leased space) | $113.2K2 Sep 30, 2025 | $141.9K2 Sep 30, 2024 | −20.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $80.5K8 Sep 30, 2024 |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $6.4M2 Sep 30, 2025 | $777.0K2 Sep 30, 2024 | +726.9% |
| Finite-lived intangibles, gross | $859.9K8 Sep 30, 2024 | $827.1K8 Sep 30, 2023 | +4.0% |
| Accumulated amortization | $82.9K8 Sep 30, 2024 | $60.7K8 Sep 30, 2023 | +36.5% |
| Finite-lived intangibles, net | $777.0K8 Sep 30, 2024 | $766.4K8 Sep 30, 2023 | +1.4% |
Inventory
Leadership
Who has led Bon Natural Life Ltd, and when. Pick a name to see everywhere that person has worked.
Chief operating officer
- Chief operating officerYingchun Xue Apr 10, 2026 to now9
Board members and other officers (3)
- Chief Marketing OfficerChen Wenjuan Apr 10, 2026 to now10
- Board memberJing Veronica Chen Apr 23, 2026 to now11
- Board memberGao Zhixiang May 15, 2026 to now12
Filings
127 filings to the SEC since October 2021: 9 annual reports, 8 insider forms, 3 large holders, 107 other. The latest 20:
- Sep 23, 20266-K EDGAR
- May 15, 20263 EDGAR
- Apr 23, 20263 EDGAR
- Apr 10, 20263 EDGAR
- Apr 10, 20263 EDGAR
- Apr 10, 20263 EDGAR
- Apr 10, 20263 EDGAR
- Apr 10, 20263 EDGAR
- Apr 10, 20263 EDGAR
- Mar 19, 20266-K EDGAR
- Feb 17, 20266-K EDGAR
- Jan 23, 202620-F EDGAR
- Dec 10, 20256-K EDGAR
- Nov 25, 20256-K EDGAR
- Nov 14, 20256-K EDGAR
- Nov 10, 2025F-3/A EDGAR
- Oct 16, 2025F-3 EDGAR
- Sep 29, 20256-K EDGAR
- Sep 9, 20256-K EDGAR
- Aug 5, 20256-K EDGAR
The 127 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- East West Capital, LLCSCHEDULE 13G/A, 3 filings Mar 17, 2025 to Mar 27, 202513
SEC filer profile
How Bon Natural Life Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBon Natural Life Ltd1
- CIK0001816815
- Filer statusNon-accelerated filer an emerging growth company; a shell company4
- Incorporated inCayman Islands4
- Fiscal year endsSeptember 301
- Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business addressRoom 601, Block C, Gazelle Valley, No.69, Jinye Road, High-Tech Zone, Xian, Shaanxi, F4 7100761
- Phone0086-29-883463011
- Shares outstanding6,086,971 Common Class A shares; 2,041,839 Common Class B shares as of Sep 30, 20254
- AuditorYCM CPA INC, Irvine, California PCAOB ID 67814
- On EDGAR sinceJul 13, 20201
- Filings152 in all: 6-K (64), CORRESP (17), UPLOAD (16), 3 (8), F-1/A (8), 20-F (5), 20-F/A (4), F-3/A (4)1
All 24 form types
EFFECT (3), 424B4 (2), 424B5 (2), DRS (2), F-1 (2), F-3 (2), NT 20-F (2), S-8 (2), SCHEDULE 13G/A (2), 8-A12B (1), CERT (1), DRS/A (1), DRSLTR (1), F-1MEF (1), FWP (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (20-F) Jan 23, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Class A Ordinary Shares, $0.025 par value | BON | NASDAQ |
From the cover page of the 20-F filed Jan 23, 2026 (Section 12(b) of the Exchange Act).4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARJing Veronica Chen, Board member
- 12SEC EDGARGao Zhixiang, Board member
- 13